Sodium glucose transporter 2 inhibitors for heart failure
Abstract
Heart failure (HF) is a leading cause of cardiovascular morbidity and mortality, affecting over 64 million individuals worldwide. Despite advances in guideline-directed medical therapy, patients with HF continue to experience poor outcomes, highlighting the need for novel therapeutic approaches. Sodium glucose transporter 2 (SGLT2) inhibitors, initially developed for diabetes management, have emerged as groundbreaking therapies for HF. These agents demonstrate remarkable cardiovascular benefits that extend beyond their glucose-lowering effects, including significant reductions in HF hospitalization and cardiovascular mortality rates. Landmark trials including Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction, and Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure have established the efficacy of SGLT2 inhibitors across the spectrum of HF phenotypes, regardless of diabetes status. The mechanisms underlying these benefits are multifaceted, involving improvements in cardiac energetics, mitochondrial function, reduction of oxidative stress, attenuation of inflammation, and favorable effects on cardiac remodeling and fibrosis. This comprehensive review examines the current evidence supporting the use of SGLT2…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.